FOLH1 and prostate carcinoma: This can be realized by radioisotopes that naturally home in on certain cell types (e.g., I‐131 to thyroid and Ra‐223 to bone), or radioisotopes conjugated to ligands that leverage receptor specificity (e.g., Lu‐177‐PSMA ligand to PSMA‐expressing prostate cancer cells, and Lu‐177‐dotatate to somatostatin‐receptor positive neuroendocrine cancer cells).